Top Page
AstraZeneca
(LSE:AZN)
AstraZeneca (AZN) vs. iShares MSCI United Kingdom ETF (EWC)
AstraZeneca Business Overview & Revenue Model
AstraZeneca Earnings Call Summary
AstraZeneca Financial Statement Overview
| Breakdown | |||||
| TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 54.98B | 54.07B | 45.81B | 44.35B | 37.42B | 26.62B | Gross Profit |
| 44.76B | 43.87B | 37.77B | 31.96B | 24.98B | 21.32B | EBIT |
| 10.56B | 10.00B | 8.19B | 3.76B | 1.06B | 5.16B | EBITDA |
| 17.73B | 15.44B | 13.91B | 9.09B | 5.11B | 8.08B | Net Income Common Stockholders |
| 7.77B | 7.04B | 5.96B | 3.29B | 112.00M | 3.20B |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 8.02B | 5.53B | 5.86B | 6.41B | 6.40B | 7.99B | Total Assets |
| 102.29B | 104.03B | 101.12B | 96.48B | 105.36B | 66.73B | Total Debt |
| 34.55B | 30.11B | 28.62B | 29.23B | 30.78B | 20.38B | Net Debt |
| 26.71B | 24.63B | 22.78B | 23.07B | 24.45B | 12.55B | Total Liabilities |
| 64.79B | 63.16B | 61.95B | 59.42B | 66.08B | 51.09B | Stockholders Equity |
| 37.45B | 40.79B | 39.14B | 37.04B | 39.27B | 15.62B |
| Cash Flow | Free Cash Flow | ||||
| 9.68B | 7.28B | 6.57B | 7.24B | 3.76B | 2.19B | Operating Cash Flow |
| 13.09B | 11.86B | 10.35B | 9.81B | 5.96B | 4.80B | Investing Cash Flow |
| -6.82B | -7.98B | -4.06B | -2.96B | -11.06B | -285.00M | Financing Cash Flow |
| -8.73B | -4.00B | -6.57B | -6.82B | 3.65B | -2.20B |
AstraZeneca Technical Analysis
AstraZeneca Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | £162.57B | 26.59 | 19.90% | 2.35% | 13.74% | 21.45% | |
78 Outperform | £37.21B | 26.17 | 8.80% | 1.60% | -0.61% | 39.00% | |
76 Outperform | £9.38B | 29.04 | 7.78% | 2.72% | 1.85% | 51.77% | |
75 Outperform | £4.66B | 16.64 | 15.79% | 2.98% | 5.83% | 83.35% | |
74 Outperform | £57.54B | 18.46 | 22.52% | 4.28% | 2.57% | -30.13% | |
53 Neutral | $5.14B | 3.23 | -45.01% | 2.85% | 17.55% | -0.69% | |
| $37.65B | 3.74 | 13.12% | 5.94% | ― | ― |
AstraZeneca Corporate Events
AstraZeneca’s Imfinzi has been recommended for approval by the CHMP in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer. The recommendation is based on the NIAGARA Phase III trial, which showed significant reductions in disease recurrence and death risk compared to neoadjuvant chemotherapy alone. This approval could transform treatment approaches in Europe, offering a new standard of care for patients with resectable muscle-invasive bladder cancer.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca’s Imfinzi has been recommended for approval in the EU as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC), based on the NIAGARA Phase III trial results. The trial demonstrated significant reductions in the risk of disease progression and death, supporting Imfinzi’s potential to become a new standard of care in Europe, offering a much-needed treatment option for MIBC patients and potentially transforming the treatment landscape.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced the vesting of ordinary shares to CEO Pascal Soriot under the AstraZeneca Performance Share Plan. The award, granted in 2020, vested after a three-year performance period and a two-year holding period, resulting in 97% of the award vesting. This transaction reflects AstraZeneca’s commitment to rewarding its leadership based on performance, potentially impacting the company’s executive compensation strategy and stakeholder perceptions.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £14500.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca has completed the acquisition of EsoBiotec, a biotechnology company known for its innovative in vivo cell therapies, particularly the Engineered NanoBody Lentiviral (ENaBL) platform. This acquisition, valued at up to $1 billion, positions AstraZeneca to enhance its cell therapy capabilities, potentially transforming cancer treatment by enabling quicker and more accessible therapies. The acquisition aligns with AstraZeneca’s strategic focus on oncology and immune-mediated diseases, aiming to redefine cancer care and address unmet needs in chronic diseases.
The most recent analyst rating on (GB:AZN) stock is a Buy with a £20000.00 price target. To see the full list of analyst forecasts on AstraZeneca stock, see the GB:AZN Stock Forecast page.
AstraZeneca announced positive results from its POTOMAC Phase III trial, where the Imfinzi regimen showed a significant improvement in disease-free survival for patients with high-risk non-muscle-invasive bladder cancer. This advancement could potentially enhance treatment options for early-stage bladder cancer, aligning with AstraZeneca’s strategy to bring novel therapies to patients where long-term benefits are most achievable. The safety profile of Imfinzi combined with BCG therapy was consistent with known profiles, and no new safety concerns were identified. These findings will be shared with global regulatory authorities, potentially impacting AstraZeneca’s market positioning and offering new hope for stakeholders involved in bladder cancer treatment.
AstraZeneca and Daiichi Sankyo announced positive results from the DESTINY-Breast11 Phase III trial, showing that Enhertu followed by THP significantly improves pathologic complete response rates in high-risk HER2-positive early-stage breast cancer patients compared to the standard of care. This trial marks the first Phase III success for Enhertu in early breast cancer and suggests a potential shift in treatment paradigms, offering a promising new approach that could improve patient outcomes and challenge existing standards.
AstraZeneca’s Calquence, in combination with bendamustine and rituximab, has been approved by the European Union for first-line treatment of adult patients with mantle cell lymphoma (MCL) who are not eligible for autologous stem cell transplant. This approval, based on the ECHO Phase III trial results, marks Calquence as the first and only BTK inhibitor approved for this indication in the EU, offering a significant improvement in progression-free survival and providing a new treatment option for patients with this aggressive form of non-Hodgkin lymphoma.
AstraZeneca announced that its fixed-dose triple-combination therapy, Breztri Aerosphere, met all primary endpoints in the Phase III KALOS and LOGOS trials for patients with uncontrolled asthma. The trials demonstrated significant improvements in lung function compared to dual-combination therapies, highlighting Breztri’s potential to improve asthma treatment. These results build on Breztri’s established efficacy in treating COPD and could expand its use to a broader patient population, enhancing AstraZeneca’s position in the respiratory care market.
AstraZeneca announced that Karen Knudsen, a Non-Executive Director, purchased 1,400 American Depositary Shares (ADSs) of the company on April 30, 2025. This transaction, priced at $71.655 per ADS, reflects potential confidence in the company’s market position and future performance, possibly impacting stakeholder perceptions positively.
AstraZeneca has announced that as of April 30, 2025, its issued share capital with voting rights consists of 1,550,638,452 ordinary shares, with no shares held in Treasury. This total number of voting rights is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules.
AstraZeneca announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended approval for a fixed-duration regimen of its drug Calquence, in combination with venetoclax, with or without obinutuzumab, for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) in the EU. This recommendation is based on the AMPLIFY Phase III trial results, which demonstrated significant improvements in progression-free survival compared to standard chemoimmunotherapy. The approval could position Calquence as a leading treatment option in Europe, offering patients a more flexible and potentially safer treatment regimen.
AstraZeneca has decided to discontinue the CAPItello-280 Phase III trial for Truqap in combination with docetaxel and androgen-deprivation therapy in patients with metastatic castration-resistant prostate cancer. This decision follows the Independent Data Monitoring Committee’s recommendation after an interim analysis indicated that the trial was unlikely to meet its primary endpoints of radiographic progression-free survival and overall survival. The company will collaborate with investigators for patient follow-up and utilize the trial data for ongoing research, highlighting the continued challenges and unmet needs in treating this aggressive form of prostate cancer.
AstraZeneca reported strong financial results for Q1 2025, with a 10% increase in total revenue driven by growth in oncology and biopharmaceuticals. The company achieved five positive Phase III study readouts and 13 approvals in major regions, reinforcing its strong growth momentum and positioning it well towards its 2030 revenue ambition. Despite ongoing investigations in China, AstraZeneca continues to expand its operations, including acquiring FibroGen China and EsoBiotec, enhancing its capabilities in cell therapies.
AstraZeneca, in collaboration with Daiichi Sankyo, announced positive interim results from the DESTINY-Breast09 Phase III trial, demonstrating that Enhertu combined with pertuzumab significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer compared to the current standard of care. This breakthrough marks a significant advancement in first-line treatment options for this aggressive cancer type, potentially delaying disease progression and offering a new hope for patients who typically face a poor prognosis.
AstraZeneca PLC announced the results of its Annual General Meeting (AGM) held on April 11, 2025, where all proposed resolutions were passed, including special resolutions 9-12. The AGM also marked the retirement of Deborah DiSanzo and Andreas Rummelt from the Board. The successful passage of these resolutions, including the re-election and election of several directors, reflects strong shareholder support and positions AstraZeneca to continue its strategic initiatives in the biopharmaceutical industry.
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been approved by the European Union for treating resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This approval is based on the AEGEAN Phase III trial, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval marks a significant step in improving outcomes for NSCLC patients in Europe, offering a new immunotherapy-based regimen that extends the time patients live without cancer recurrence. This development underscores AstraZeneca’s commitment to transforming care in early-stage lung cancer, where there is significant potential for cure.
AstraZeneca and Daiichi Sankyo’s Enhertu has been approved by the European Union as the first HER2-directed therapy for patients with HR-positive, HER2-low, or HER2-ultralow metastatic breast cancer following endocrine therapy. This approval, based on the DESTINY-Breast06 Phase III trial results, positions Enhertu as a superior alternative to chemotherapy, offering a median progression-free survival of over a year. The approval expands the eligible patient population and marks a significant advancement in breast cancer treatment, potentially impacting AstraZeneca’s market positioning and providing new treatment options for patients.
AstraZeneca PLC has announced its issued share capital with voting rights as of March 31, 2025, totaling 1,550,623,487 ordinary shares. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
AstraZeneca’s Calquence, in combination with bendamustine and rituximab, has been recommended for approval by the CHMP in the EU for first-line treatment of mantle cell lymphoma (MCL), marking it as the first BTK inhibitor for this indication. The recommendation is based on the ECHO Phase III trial results, which showed a significant improvement in progression-free survival, potentially transforming the standard of care for MCL patients in Europe.
AstraZeneca’s Imfinzi has been approved by the FDA as the first perioperative immunotherapy for muscle-invasive bladder cancer (MIBC) in the US, following the successful NIAGARA Phase III trial. This approval marks a significant advancement in treatment, offering a new standard of care by reducing the risk of disease recurrence and death, and is expected to transform clinical approaches to MIBC, providing new hope for patients and stakeholders.
AstraZeneca has announced a $2.5 billion investment to establish a new global strategic R&D center in Beijing, marking its second in China and sixth worldwide. This initiative, in partnership with the Beijing Municipal Government, includes collaborations with biotech firms Harbour BioMed, Syneron Bio, and BioKangtai, and aims to advance life sciences in China. The investment will enhance AstraZeneca’s early-stage research and clinical development capabilities, supported by a state-of-the-art AI and data science laboratory. Additionally, AstraZeneca is forming a joint venture with BioKangtai to develop vaccines, marking its first vaccine manufacturing facility in China. This strategic move is expected to grow AstraZeneca’s Beijing workforce to 1,700 employees and strengthen its position in the global biopharmaceutical industry.
AstraZeneca announced that its investigational drug eneboparatide met the primary endpoint in the Phase III CALYPSO trial, showing significant efficacy in normalizing serum calcium levels in adults with chronic hypoparathyroidism at 24 weeks. This result highlights eneboparatide’s potential as a new treatment option for this rare endocrine disorder, which affects over 200,000 people in the US and EU. The trial will continue to 52 weeks to further assess the drug’s risk-benefit profile, with full data expected to be shared with global health authorities and presented at medical meetings.
AstraZeneca’s Imfinzi has been approved by the European Union as the first immunotherapy for limited-stage small cell lung cancer (LS-SCLC), following the successful ADRIATIC Phase III trial. This approval marks a significant advancement in treatment options, as Imfinzi demonstrated a 27% reduction in the risk of death compared to placebo, offering a new benchmark for LS-SCLC care and potentially transforming outcomes for patients in Europe.
AstraZeneca has announced its acquisition of EsoBiotec, a biotechnology company specializing in in vivo cell therapies, for up to $1 billion. This acquisition includes EsoBiotec’s ENaBL platform, which could revolutionize cell therapy by allowing treatments to be delivered in minutes rather than weeks, potentially transforming the patient experience and expanding access to these therapies. The move is expected to enhance AstraZeneca’s cell therapy capabilities and accelerate its ambition to harness the full potential of cell therapies, marking a significant step forward in its oncology and immune-mediated disease treatment strategies.
The Capital Group Companies, Inc., a U.S.-based investment management firm, has increased its voting rights in AstraZeneca PLC to 5.000629% as of March 10, 2025. This acquisition of voting rights highlights the firm’s strategic interest in AstraZeneca, potentially impacting the company’s shareholder dynamics and signaling confidence in AstraZeneca’s market positioning.
AstraZeneca PLC announced that on March 4, 2025, its CEO Pascal Soriot and CFO Aradhana Sarin received awards of ordinary shares under the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP). These awards are part of the company’s incentive plans, with shares under the AZDBP representing deferred portions of annual bonuses and subject to a three-year holding period. The AZPSP awards are contingent on performance measures over three years, with a subsequent two-year holding period, reflecting AstraZeneca’s focus on aligning executive compensation with long-term performance goals.
AstraZeneca PLC announced that as of 28 February 2025, its issued share capital with voting rights consists of 1,550,607,175 ordinary shares, with no shares held in Treasury. This figure is crucial for shareholders to determine their notification requirements under the UK Financial Conduct Authority’s Disclosure and Transparency Rules, impacting how they manage their interests in the company.
AstraZeneca’s Imfinzi, in combination with chemotherapy, has been recommended for approval by the CHMP in the EU for treating adults with resectable non-small cell lung cancer (NSCLC) at high risk of recurrence. This recommendation is based on the AEGEAN Phase III trial results, which demonstrated a 32% reduction in the risk of recurrence, progression, or death compared to neoadjuvant chemotherapy alone. The approval could significantly enhance AstraZeneca’s position in the oncology market, providing a new treatment option for patients with early-stage lung cancer, addressing a high unmet medical need.
AstraZeneca, in collaboration with Daiichi Sankyo, announced that their drug Enhertu has been recommended for approval in the EU for treating patients with HER2-low or HER2-ultralow metastatic breast cancer, based on the DESTINY-Breast06 Phase III trial results. This recommendation by the Committee for Medicinal Products for Human Use (CHMP) marks a significant advancement in breast cancer treatment, offering a new HER2-directed therapy option for patients who have progressed on endocrine therapy, potentially improving outcomes and shifting current treatment paradigms.